echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: T cell receptor pool of tumor-infiltrating T cells can predict the prognosis of cancer patients

    Nat Commun: T cell receptor pool of tumor-infiltrating T cells can predict the prognosis of cancer patients

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PD1 (programmed death receptor 1) immune checkpoint blockade (CPB) therapy is increasingly used to treat metastatic solid tumors, and the response rate of patients is 20-55%


    PD1 (programmed death receptor 1) immune checkpoint blockade (CPB) therapy is increasingly used to treat metastatic solid tumors, and the response rate of patients is 20-55%


    However, it is still a big problem to identify patients who


    There is an urgent need to identify predictive biomarkers of patient care to identify patients with metastatic cancer that respond better to CPB


    Previous studies have shown that tumor infiltration of T cells is essential for an effective anti-cancer immune response




    TIL/Tc TCR can predict patient's overall survival rate and response to PD1 CPB

    TIL/Tc TCR can predict patient's overall survival rate and response to PD1 CPB

    All in all, the results of the study reveal that in various cancers including melanoma, the diversity of TIL/Tc can predict the overall survival (OS) of patients without PD1 blockade, while TIL/Tc before treatment The type of clone can predict the patient's response to anti-PD1 treatment


    The results of the study revealed that in various cancers including melanoma, the diversity of TIL/Tc can predict the overall survival (OS) of patients without PD1 blockade, and the clone of TIL/Tc before treatment Type can predict the patient's response to anti-PD1 treatment



    The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.